Many of these conclusions were based on experiments which employed treatment of cell lines representing different normal or cancer types with pan-CDK inhibitors (table 1), or employed overexpression of dominant-negative CDK5 constructs, or expression of anti-CDK5 siRNAs or shRNAs. Here, CDK5 is linked to cancer.